CoreLine Soft Co Ltd
CoreLine Soft has a market price of 3,405 KRW and a market capitalization of 62,569,006,530 KRW, with a price-to-book ratio of 3.44 and a price-to-tangible-book ratio of 3.44. The company's enterprise value to EBITDA is -5.72, and its enterprise value to revenue is 17.94, indicating a high valuation relative to its revenue but a negative EBITDA. The company's return on equity is -79.77%, and its return on assets is -35.54%, both significantly below industry norms. The company's profitability is challenged, with a net loss of 14,496,260,920 KRW and an operating loss of 13,444,847,760 KRW. Its gross profit of 3,933,580,050 KRW is modest compared to its total revenue of 4,283,668,050 KRW, indicating high cost structures or low pricing power. The company's debt-to-equity ratio is 0.79, and its current ratio is 1.45, suggesting moderate liquidity but a need for careful debt management. CoreLine Soft's revenue is concentrated in a single business segment focused on AI-based medical image analysis software, with no disclosed geographic diversification. The company's operating cash flow is negative at -11,614,606,740 KRW, and its free cash flow is -17,069,904,670 KRW, indicating a reliance on external financing. Capital expenditures of -3,395,745,750 KRW suggest ongoing investment in infrastructure or technology. The company's outlook for the current fiscal year is uncertain, with no disclosed revenue growth or decline. The company's historical revenue of 4,283,668,050 KRW is relatively flat, and there is no indication of a significant growth trajectory. The company's risk assessment indicates medium liquidity risk and low dilution risk, but key flags include negative net cash after subtracting total debt. Recent events and filings do not provide specific details on the company's strategic initiatives or financial performance. The company's financial health is constrained by its negative operating and net income, and its reliance on external financing to sustain operations. The company's capital structure and liquidity position require close monitoring to assess its ability to meet short-term obligations. The company's risk profile is influenced by its high debt levels and negative cash flows, which could impact its ability to invest in growth opportunities. The company's dilution risk is low, but its liquidity risk remains a concern due to its negative net cash position. The company's financial performance and strategic direction will be critical in determining its long-term viability.
Business. CoreLine Soft Co Ltd develops and supplies artificial intelligence (AI) based medical image analysis software for computed tomography (CT) images of the chest, head, and neck, primarily assisting medical staff in diagnosis and treatment support.
Classification. CoreLine Soft is classified in the Healthcare sector under the Advanced Medical Equipment & Technology industry with a confidence level of 0.92.
- CoreLine Soft has a high price-to-book ratio of 3.44, indicating a premium valuation relative to its book value.
- The company's return on equity is -79.77%, and its return on assets is -35.54%, both significantly below industry norms.
- CoreLine Soft's operating and net income are negative, with a net loss of 14,496,260,920 KRW and an operating loss of 13,444,847,760 KRW.
- The company's liquidity risk is medium, and its dilution risk is low, but key flags include negative net cash after subtracting total debt.
- The company's operating cash flow is negative at -11,614,606,740 KRW, and its free cash flow is -17,069,904,670 KRW, indicating a reliance on external financing.
- --
- # RATIONALES
- ```json
- Net cash is negative after subtracting total debt.